Add To Watchlist
Share URL
About The Company
Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel.
Read More
Overview
Value
1
Growth
29
Health
55
Management
57
Analyst Opinion
60
Total
40
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Poor earnings and cashflow growth 0
Latest News
Why Is PainReform (PRFX) Stock Up 48% Today?
InvestorPlace | 12:54 Wed 8 Feb 2023
Read More →
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire | 14:00 Thu 1 Sept 2022
Read More →
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
GlobeNewsWire | 14:25 Mon 21 Mar 2022
Read More →
PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today
InvestorPlace | 16:58 Mon 22 Nov 2021
Read More →
Market Peers
PRFX
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-265.99%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
-4.49%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.5 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-140.52%
PE/Earnings Growth
N/A
Price/Book
0.58x
Growth
Growth Score
29
- ✔ Revenue growth has improved this yeara
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 9.63% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
9.63%
Health
Health Score
55
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
N/Ax
Current Assets/Liabilities
6.56x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
57
Average Buybacks/Dilution
-4.49%
Recent Buybacks/Dilution
-0.00%
5 Year Price Volitility
78.39%
Return On Assets
-20.58%
Return On Capital Employed
-20.67%
Return On Equity
-24.11%
Return On Free Cashflow
74.61%
Return On Investments
N/A
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
PainReform Ltd.
Currency
USD
Beta
-0.326489
Vol Avg
15503
Ceo
Dr. Ehud Geller Ph.D.
Cik
0001801834
Cusip
Exchange
NASDAQ Capital Market
Full Time Employees
4
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
2020-09-01
Address
60C Medinat Hayehudim Street
City
Herzliya
State
Country
IL
Zip
6745442
Phone
972 9 960 1901
All financial data provided by FMP